Study links clot-buster, angioplasty combo with increased death risk

09/7/2005 | USA Today

Many heart attack patients are given a clot-busting drug prior to a planned angioplasty, but the combined treatment could increase a patient's risk of death following the artery-widening procedure, according to a new study. Researchers studying 1,667 patients found that 6% of patients given the clot-busting drug TNKase died within 30 days of their angioplasty, compared with just 3.8% of those who had an angioplasty with no clot-buster.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX